Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Kindred Biosciences
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020